Menopause · Nov 17, 2026
Updated clinical recommendations for cardiovascular risk assessment to facilitate hormone therapy prescribing: incorporating PREVENT risk calculator and the 2026 multisociety lipid guidelines
By Shufelt CL, Stuenkel CA, Lau ES et al.
Cardiovascular disease (CVD) remains the leading cause of death among women and is a key consideration when evaluating candidates for menopausal hormone therapy (HT). Over the past two decades, recommendations regarding HT use have evolved substantially and now include the understanding that cardiovascular risk varies according to age, time since menopause onset, and baseline cardiovascular health. Consequently, cardiovascular risk assessment has become an integral component of menopause management. The recent introduction of the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator and incorporation of PREVENT into the 2026 American College of Cardioloty/Amercian Heart Association multisociety dyslipidemia guideline represent an important shift in CVD prevention. PREVENT includes contemporary cardiovascular-kidney-metabolic risk factors and estimates both 10-year and 30-year cardiovascular risk for adults ages 30-79 years without known CVD. Concurrently, updated lipid management recommendations emphasize individualized risk assessment and consideration of risk-enhancing factors, and in some cases, coronary artery calcium scoring, along with more explicit lipid-lowering targets. This perspective provides a practical framework for integrating PREVENT-derived risk categories into menopause care. We outline cardiovascular risk stratification strategies for women considering HT, discuss the role of coronary artery calcium scoring and female-specific risk enhancers, and align contemporary lipid management recommendations with decisions regarding initiation of HT, including route of administration. By integrating cardiovascular risk assessment and menopause management, clinicians can optimize cardiovascular risk reduction and individualize treatment decisions for symptomatic midlife women.
doi.org/10.1097/gme.0000000000002953PubMed 43042547Biomarkers